Mitigating GLP-1 Related Dermatologic Adverse Effects Through Methylene Blue's Antioxidant Action
June 2026
in “
Annals of Clinical Pathology
”
Studysummary This review discusses how glucagon-like peptide-1 receptor agonists, used for type 2 diabetes and obesity, may cause skin aging and hair loss, and explores methylene blue as a potential protective treatment.
Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
Read the full study on jscimedcentral.com →